Lenvervimab
Lenvervimab (INN;[1] development code GC1102) is a monoclonal antibody that is being investigated for hepatitis B.
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Humanized |
| Target | hepatitis B virus surface antigen |
| Clinical data | |
| Other names | GC1102 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| UNII | |
This drug is being developed by GC Pharma. As of 2018, lenvervimab is undergoing Phase II/III trials.
References
- World Health Organization (2017). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 118" (PDF). WHO Drug Information. 31 (4).
This article is issued from
Wikipedia.
The text is licensed under Creative
Commons - Attribution - Sharealike.
Additional terms may apply for the media files.